OPKO HEALTH, INC. 8-K

What Happened OPKO Health, Inc. filed an 8-K for its June 18, 2026 Annual Meeting of Stockholders reporting that all eleven director nominees were elected and shareholders approved several key proposals. The meeting ratified Ernst & Young LLP as the company’s independent auditor for fiscal 2026 and approved the Company’s 2026 Equity Incentive Plan and the advisory “say-on-pay” vote.

Key Details

• All 11 director nominees were elected. Votes "for" ranged from 398,032,505 (John A. Paganelli) to 454,992,813 (Subbarao V. Uppaluri, Ph.D.); several directors received between ~420M–428M votes. There were broker non-votes of 79,767,645 on director and other non-ratification proposals.
• 2026 Equity Incentive Plan approved: For 440,096,997; Against 23,694,041; Abstain 348,125; Broker Non‑Votes 79,767,645.
• Advisory approval of executive compensation (say-on-pay): For 446,238,170; Against 17,487,326; Abstain 413,667; Broker Non‑Votes 79,767,645.
• Ratification of independent auditor (Ernst & Young LLP) for 2026: For 535,070,921; Against 6,120,699; Abstain 2,715,188 (no broker non‑votes).

Why It Matters These vote outcomes confirm board continuity and shareholder backing for OPKO’s governance actions. Approval of the 2026 Equity Incentive Plan enables the company to grant equity awards to employees and directors going forward, while the favorable advisory vote on executive pay signals shareholder support for management compensation. Ratifying Ernst & Young ensures continuity of the company’s external audit relationship for fiscal 2026. The results were filed and signed on June 18, 2026 by Steven D. Rubin (Executive VP - Administration).